<DOC>
	<DOCNO>NCT01450072</DOCNO>
	<brief_summary>The Departments Neurology Neurosurgery conduct research study evaluate safety effectiveness intravascular angioplasty treatment venous narrow treatment Multiple Sclerosis ( MS ) .</brief_summary>
	<brief_title>Prospective Randomized Endovascular Therapy Multiple Sclerosis - PREMiSE</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Age 1865 year EDSS 06.5 ( 05.5 phase II study ) Diagnosis relapse MS accord McDonald criterion ( Polman et al. , 2005 ) 1 relapse within past 12 month GAD positive lesion MRI within past 3 month ( phase II study ) Be treatment currently FDA approve diseasemodifying treatment ( exclude Tysabri steroid ( within last 30 day prior enrollment ) Evidence â‰¥2 sonographic parameter suspicious abnormal extracranial cerebral venous outflow ( see Table 1 background 1.5 section ) Normal renal function : creatinine clearance level &gt; 60 Relapse , disease progression Tysabri steroid treatment 30 day precede study entry Preexisting medical condition know associated brain pathology ( e.g. , neurodegenerative disorder , cerebrovascular disease , positive history alcohol abuse , etc . ) Severe peripheral chronic venous insufficiency Abnormal renal function Contrast allergy ( anaphylaxis ) Not accept undergo endovascular treatment Peripheral Vascular Disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>